Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -48.43% is 55% above its 5-year average of -106.63%, near the high end of its 5-year range (-361.39%–-33.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.53% above its 12-month average of -56.67%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -48.43%.
RETURN ON EQUITY (ROE)
-48.43%
RETURN ON EQUITY (ROE) AVG TTM
-56.67%
RETURN ON EQUITY (ROE) AVG 3Y
-84.34%
RETURN ON EQUITY (ROE) AVG 5Y
-106.63%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.53%
CURRENT VS 3Y AVG
+42.57%
CURRENT VS 5Y AVG
+54.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
-18.45%
vs the sector median at left
Immunome, Inc.
Market Cap
$1.90B
Return on Equity (ROE)
-48.43%
TTM Avg
-56.67%
3Y Avg
-84.34%
5Y Avg
-106.63%
Market Cap
$1.90B
Return on Equity (ROE)
-40.09%
TTM Avg
4.56%
3Y Avg
-13.84%
5Y Avg
-2.18%
Market Cap
$1.91B
Return on Equity (ROE)
-179.99%
TTM Avg
-188.10%
3Y Avg
28.98%
5Y Avg
-2.67%
Market Cap
$1.89B
Return on Equity (ROE)
12.01%
TTM Avg
-4.52%
3Y Avg
-16.89%
5Y Avg
-11.36%
Market Cap
$1.85B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.84B
Return on Equity (ROE)
N/A
TTM Avg
-157.29%
3Y Avg
-33.70%
5Y Avg
49.06%
Market Cap
$1.84B
Return on Equity (ROE)
-28.45%
TTM Avg
-88.46%
3Y Avg
-128.76%
5Y Avg
-100.86%
Market Cap
$1.96B
Return on Equity (ROE)
-13.09%
TTM Avg
-10.89%
3Y Avg
-18.29%
5Y Avg
-19.41%
Market Cap
$1.83B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.28%
3Y Avg
-6.47%
5Y Avg
-2.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.90B | -48.43% | -56.67% | -84.34% | -106.63% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | -40.09% | 4.56% | -13.84% | -2.18% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | -179.99% | -188.10% | 28.98% | -2.67% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 4.88% | 4.47% | 6.79% | 5.89% |
| Novavax, Inc. (NVAX)vs › | $1.84B | N/A | -157.29% | -33.70% | 49.06% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -28.45% | -88.46% | -128.76% | -100.86% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | -13.09% | -10.89% | -18.29% | -19.41% |
| Azenta, Inc. (AZTA)vs › | $1.83B | -8.14% | -6.28% | -6.47% | -2.03% |
| Xencor, Inc. (XNCR)vs › | $1.84B | -32.46% | -24.39% | -19.07% | -12.85% |
ROE
-48.4%
ROA
-45.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -48.43% |
| 2026-03-31 | -38.15% |
| 2025-12-31 | -33.48% |
| 2025-09-30 | -84.40% |
| 2025-06-30 | -78.87% |
| 2025-03-31 | -66.78% |
| 2024-12-31 | -161.71% |
| 2024-09-30 | -142.08% |
| 2024-06-30 | -103.45% |
| 2024-03-31 | -81.25% |
| 2023-12-31 | -89.09% |
| 2023-09-30 | -361.39% |
| 2023-06-30 | -280.00% |
| 2023-03-31 | -212.91% |
| 2022-12-31 | -221.56% |
| 2022-09-30 | -160.12% |
| 2022-06-30 | -119.39% |
| 2022-03-31 | -85.72% |
| 2021-12-31 | -51.28% |
| 2021-09-30 | -38.20% |
| 2021-06-30 | -35.62% |
| 2021-03-31 | -50.31% |
| 2020-12-31 | -43.14% |
| 2020-06-30 | -121.60% |
| 2020-03-31 | -328.69% |
